Europe is emerging as an attractive route to global market access for Chinese sponsors. Early consideration of EMA requirements can help avoid costly delays and improve approval success. Read the article: https://ow.ly...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
AI tools life sciences companies
This BioSpectrum Asia piece highlights the AI tools leading organisations are already putting to work—an important look at where practical adoption is delivering real impact across the industry with contributions from Tony Clarke, SVP of Enterprise AI at ICON.
-
ICON expands early phase capabilities
Opens new Clinical Research Unit and satellite outpatient clinics.
-
ICON opens new Texas clinical research unit
ICON boosts early phase trials with new San Antonio facility, enhancing participant care and operational efficiency.
-
ICON opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities
The San Antonio facility includes a clinic, pharmacy, laboratory and investigational product handling services intended to improve dosing efficiency, protocol modifications and delivery timelines for sponsors.
-
Aging with HIV: What the next major challenge is for drug development
As people with HIV live longer due to ART, new challenges are emerging. Aging with HIV is linked to higher risks of comorbidities, chronic inflammation, and drug interactions, while gaps in clinical trial inclusion and care models highlight the need for more integrated, patient-centered treatment strategies.
-
Banyan BioInnovations launces with ICON support
$100M Biotech investment fund announces collaboration with ICON designed to improve trial execution and design, as well as commercialisation strategy.
-
Banyan BioInnovations debuts with $100M+ and ICON
A new biotech investment firm launches with more than $100 million in initial commitments from life science investors. ICON is both a strategic collaborator and an equity investor.
-
Overcoming Formulation Challenges for Biosimilars
Media article discussing how high-concentration formulations and patient centricity are challenges to the formulation of biosimilars, which already face patent protection barriers.
-
Recentring sites: The human factors slowing study start-up and how to resolve them
In the Journal for Clinical Studies article, Brian Mallon explores the human factors slowing study start‑up and outlines how a more site‑centred approach can accelerate activation, recruitment and retention.
-
Partnership set to make therapies ‘reach patients sooner’
ICON's partnership with Advarra will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
